BACKGROUND: Coinfection with the flavivirus GB virus C (GBV-C) is frequent in patients suffering from HIV type-1 (HIV-1) infection because of shared routes of transmission. GBV-C coinfection has been proposed to exert a beneficial influence on HIV-1 infection. In vitro studies demonstrated down-regulation of C-C chemokine receptor type 5 (CCR5) as a potential mechanism by which GBV-C modulates HIV-1 disease progression. We therefore studied surface expression of the two major HIV-1 coreceptors, CCR5 and CXC chemokine receptor type 4 (CXCR4), on CD4(+) and CD8(+) T-cells in 128 HIV-1-positive patients stratified with respect to their GBV-C status, immune function and highly active antiretroviral therapy (HAART) status in vivo. METHODS: GBV-C infection was studied in 128 HIV-1-infected patients by nested reverse transcriptase PCR. Fluorescence-activated cell sorting analysis was used to measure CCR5 and CXCR4 surface expression on CD4(+) and CD8(+) T-cells. RESULTS: GBV-C RNA replication was detected in 30% (38/128) of patients. In HIV-1-positive patients with advanced immunodeficiency, we found up-regulation of CCR5 surface expression on CD4(+) T-cells; however, in patients with GBV-C coinfection, no up-regulation of CCR5 CD4(+) T-cells was detected. Furthermore, CXCR4 surface expression was reduced in GBV-C-coinfected patients. These findings were independent of HAART status and HIV-1 viral load. HIV-1 coreceptor expression on CD8(+) T-cells was not altered in patients with GBV-C coinfection. CONCLUSIONS: GBV-C coinfection in HIV-1 disease leads to reduced expression of the two major HIV-1 coreceptors, CCR5 and CXCR4, on CD4(+) T-cells in patients at an advanced stage of immunodeficiency, providing a possible molecular explanation for the clinical benefit of GBV-C coinfection in late-stage HIV-1 disease.
BACKGROUND: Coinfection with the flavivirus GB virus C (GBV-C) is frequent in patients suffering from HIV type-1 (HIV-1) infection because of shared routes of transmission. GBV-C coinfection has been proposed to exert a beneficial influence on HIV-1 infection. In vitro studies demonstrated down-regulation of C-C chemokine receptor type 5 (CCR5) as a potential mechanism by which GBV-C modulates HIV-1 disease progression. We therefore studied surface expression of the two major HIV-1 coreceptors, CCR5 and CXC chemokine receptor type 4 (CXCR4), on CD4(+) and CD8(+) T-cells in 128 HIV-1-positivepatients stratified with respect to their GBV-C status, immune function and highly active antiretroviral therapy (HAART) status in vivo. METHODS:GBV-Cinfection was studied in 128 HIV-1-infectedpatients by nested reverse transcriptase PCR. Fluorescence-activated cell sorting analysis was used to measure CCR5 and CXCR4 surface expression on CD4(+) and CD8(+) T-cells. RESULTS:GBV-C RNA replication was detected in 30% (38/128) of patients. In HIV-1-positivepatients with advanced immunodeficiency, we found up-regulation of CCR5 surface expression on CD4(+) T-cells; however, in patients with GBV-C coinfection, no up-regulation of CCR5CD4(+) T-cells was detected. Furthermore, CXCR4 surface expression was reduced in GBV-C-coinfected patients. These findings were independent of HAART status and HIV-1 viral load. HIV-1 coreceptor expression on CD8(+) T-cells was not altered in patients with GBV-C coinfection. CONCLUSIONS:GBV-C coinfection in HIV-1 disease leads to reduced expression of the two major HIV-1 coreceptors, CCR5 and CXCR4, on CD4(+) T-cells in patients at an advanced stage of immunodeficiency, providing a possible molecular explanation for the clinical benefit of GBV-C coinfection in late-stage HIV-1 disease.
Authors: B J Dille; T K Surowy; R A Gutierrez; P F Coleman; M F Knigge; R J Carrick; R D Aach; F B Hollinger; C E Stevens; L H Barbosa; G J Nemo; J W Mosley; G J Dawson; I K Mushahwar Journal: J Infect Dis Date: 1997-02 Impact factor: 5.226
Authors: J Reynes; P Portales; M Segondy; V Baillat; P André; O Avinens; M C Picot; J Clot; J F Eliaou; P Corbeau Journal: AIDS Date: 2001-09-07 Impact factor: 4.177
Authors: Maria Teresa Maidana-Giret; Tânia M Silva; Mariana M Sauer; Helena Tomiyama; José Eduardo Levi; Katia C Bassichetto; Anna Nishiya; Ricardo S Diaz; Ester C Sabino; Ricardo Palacios; Esper Georges Kallas Journal: AIDS Date: 2009-11-13 Impact factor: 4.177
Authors: Jinhua Xiang; Sarah L George; Sabina Wünschmann; Qing Chang; Donna Klinzman; Jack T Stapleton Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Jack T Stapleton; Jeffrey A Martinson; Donna Klinzman; Jinhua Xiang; Seema N Desai; Alan Landay Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Jack T Stapleton; Jinhua Xiang; James H McLinden; Nirjal Bhattarai; Ernest T Chivero; Donna Klinzman; Thomas M Kaufman; Qing Chang Journal: Trans Am Clin Climatol Assoc Date: 2014
Authors: Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer Journal: J Infect Dis Date: 2012-03-20 Impact factor: 5.226
Authors: Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton Journal: Virology Date: 2012-05-16 Impact factor: 3.616
Authors: James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang Journal: J Gen Virol Date: 2013-01-03 Impact factor: 3.891
Authors: Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Alan L Landay; Ernest T Chivero; Jack T Stapleton Journal: J Immunol Date: 2013-05-17 Impact factor: 5.422